Researchers have unveiled a gene-network modeling framework that captures long-range regulatory interactions across six brain regions, tripling the number of known schizophrenia-associated genes. The study, published by the team, identified 766 total genes tied to the disorder—641 of which had never before been linked to schizophrenia.
The approach integrates both cis-regulatory elements, located near their target genes, and trans-acting factors, which can exert influence from distant genomic regions. By mapping these long-range networks, the model uncovered a much broader genetic architecture than traditional genome-wide association studies (GWAS) have provided, which typically focus on cis effects alone.
This expanded gene set may offer new targets for drug development, particularly for pathways involved in synaptic function and neurodevelopment. However, the findings are computational and require experimental validation in cell or animal models before clinical applications can be considered.
Lead author Dr. [name not provided] noted that the framework could be adapted to study other polygenic psychiatric conditions, such as bipolar disorder and autism. But experts caution that translating these genetic discoveries into therapies remains a long-term challenge, given the complexity of the brain and the lack of functional confirmation.
Regulatory and access hurdles are significant: any drug developed from these targets would need to navigate years of preclinical and clinical trials. The study underscores the gap between genetic discovery and therapeutic delivery, a persistent issue in psychiatric genomics.